[Economic evaluation of blood stem-cells autologous transplantation].
Economic evaluation of autologous peripheral blood stem cell (PBSC) transplantation certainly played a role in the very fast substitution from bone marrow to BC autograft. Economic evaluation is still ongoing about the optimization of the procedure by assessing the cost-effectiveness ratio of each new improvement of the technique. Among these improvements we present the administration of high dose CD34+ cells, the delayed administration of G-CSF and the outpatient management of post-graft follow-up. It is still very rare in the field of health economics to notice such an early and ongoing economic evaluation of an innovation.
Corroller
A G
AG
Economistes, Inserm 1. Institut Paoli-Calmettes, 232, bd Sainte-Marguerite, 13273 Marseille.
Fortanier
C
C
Faucher
C
C
Blaise
D
D
Moatti
J P
JP
D000553:Ambulatory Care / Q000191:economics; D016026:Bone Marrow Transplantation / Q000191:economics*; D002452:Cell Count; D003365:Costs and Cost Analysis; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation / Q000191:economics*; D006760:Hospitalization / Q000191:economics; D006801:Humans; D014182:Transplantation, Autologous
D016179:Granulocyte Colony-Stimulating Factor
L'évaluation économique de l'autogreffe de cellules souches du sang périphérique.